It was only recently that these two companies were among fund managers’ top 10 preferred stocks. The replacement came during a month when key stock indices remained weak marked with steep volatility. Sun Pharmaceuticals, in particular, deserves special mention as in late April minority shareholder Daiichi Sankyo had offloaded its entire 8.93 per cent stake. The stock had fallen over eight per cent as there was an increased supply of nearly 214 million shares. Fund managers had purchased about 27 million new shares of the company at a cost price of Rs 2,534 crore. With this, they more than doubled the number of shares in their holdings to 47.18 million shares against 20.18 million shares. As on 31 May, fund mangers allocated 1.25 per cent of total equity assets or Rs 3,727 crore.
It is probably the first time after a long phase that a pharma company has emerged among the most sought after stocks by fund managers. HCL Technologies, on the other hand, is the second IT stock to be in the top most allocated company in fund managers' radar along with Infosys. Fund managers believe IT could be a good contrary bet as stocks have already been beaten a lot. Put together, fund managers have allocated Rs 3,714 crore as on May 31.
Research analyst with Angel Broking has maintained a buy on HCL Technologies with a target of Rs 683. In its report, the brokerage said, “The (HCL) management remains confident of reverting back to the original profitability by FY18. We expect a CAGR of 20 per cent in dollar revenue over 2015 to 2017.”
As on 31 May, the overall equity asset under management stood at Rs 3.65 lakh crore.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)